An exciting development pipeline in pharma.
![](http://5jg.9b3.myftpupload.com/wp-content/uploads/2024/07/Pipeline240716-4-1024x627.png)
- Clascoterone solution: A novel androgen receptor inhibitor that targets androgen receptors in the scalp and is currently being studied for the treatment of androgenetic alopecia (AGA).
- CB-03-10 (Cortexolone 17α-valerate-21-propionate): Oral androgen receptor (AR) antagonist against solid tumors. It has the potential for first- and second-line therapy in pancreatic and colon cancers. Regulatory Toxicology shows oral dosing is safe and well-tolerated.
- CB-01-33 (colesevelam): Colesevelam formulated with Cosmo’s proprietary technology has the potential to overcome the current concerns for bile acid sequestrants for the treatment of bile acid diarrhea (BAD).
- CB-01-35 (Rifamycin 1% enema): An innovative product which combines an in situ gelling solution of Rifamycin and a newly designed delivery device, which is under development for the treatment of distal Ulcerative Colitis and Proctitis.